& human disease conference
November 22-26, 2022
All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.
DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.
The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.
Palais du Grand Large, St Malo, Bretagne, France
Department of Anatomy
& Developmental Biology,
Graduate School of Medicine,
Kyoto University, Kyoto, Japan
Peter P. DE DEYN
Department of Neurology,
General Hospital Middelheim and Institute Born-Bunge University of Antwerp,
Mariona ARBONES, Barcelona, Spain
Insights into the early neurogenic defects in DYRK1A haplo-insufficient syndrome
Walter BECKER, Aachen, Germany
DYRK1B – a cancer drug target?
Mara DIERSSEN, Barcelona, Spain
Role of DYRK1A in glucose homeostasis and food intake
Jean DELABAR, Paris, France
DYRK1A, biomarker of target for Alzheimer's disease?
Peter DE DEYN, Antwerpen, Belgium
Down syndrome, Alzheimer’s disease & DYRK1A
Masatoshi HAGIWARA, Kyoto, Japan
Development of inhibitors of CDK9, CLK1 and DYRK1A, and their clinical applications
Yann HERAULT, Strasbourg, France
DYRK1A dosage and cognition deficit in animal models of human disease
Nathalie JANEL, Paris, France
DYRK1A interactants, a link between Down's syndrome and its comorbidities
Bernard KHOR, Seattle, USA
DYRK family members and autoimmunity
Stefan KNAPP, Frankfurt, Germany
Selective targeting of kinases regulation RNA splicing
Akiko KOBAYASHI, Kyoto, Japan
Neuroprotection through suppression of inflammation by DYRK inhibitors
Reinhardt W. KÖSTER, Braunschweig, Germany
A zebrafish model for studying DYRK1A hyperactivity in the cerebellum
Sébastien MALINGE, Perth, Australia
DYRK1A and Acute Lymphoblastoid Leukemia
Laurent MEIJER, Roscoff, France
Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical
Christopher MEISINGER, Freiburg, Germany
The role of DYRK1A in mitochondrial protein import
Jamileh MOVASSAT, Paris, France
DYRK1A inhibitors for beta cell proliferation to treat diabetes
Lucas PELKMANS, Zurich, Switzerland
DYRK kinases as regulators of intracellular condensates
Amélie PITON, Illkirch, France
Characterization of DYRK1A syndrome, a frequent form of neurodevelopmental disorder
Congenital heart defects in Down Syndrome are caused by inscreased dosage of DYRK1A
The final program will be available in October 2022.
Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), address, e-mail contact, abstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.
Submit abstract as an attached Word document, through the Conference e-mail address (email@example.com), with your name as ‘subject’.
Abstract submission deadline: September 30, 2022.
Instructions for speakers
There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).
Very early bird registration deadline: July 31, 2022.
Early bird registration deadline: September 4, 2022.
Late registration: September 4 up to October 31, 2022.
Start of the conference: November 22, 2022 at 17:00.
End of the conference: November 26, 2022 at 12:00.
Registration comprises access to all conferences, program, coffee/tea breaks and lunches.
Very early bird registration deadline:
Industry: 600 € Academy: 500 € PhD Students*: 300 €.
Early bird registration deadline:
Industry: 800 € Academy: 600 € PhD Students*: 400 €.
Industry: 1000 € Academy: 700 €. PhD Students*: 500 €.
* Photocopy of student card required
Please consult our list of accommodation here.
Travel grants for young researchers
The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers. Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/
Getting to Saint-Malo
The easiest: Fast train (TGV) from Paris-Montparnasse train station.
Please consult our information for international access here.